MYC and neoplasm: Both strategies showed a marked anticancer effect in c-Myc mice, decreasing tumor growth and target genes expression, but failed to repress tumor growth of AKT/Ras mice, perhaps due to their more rapid growth, underlining the importance to test miRNA-based therapeutics in different animal models and suggesting again the need for patient stratification based on genomic and transcriptomic backgrounds [21].